- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03719612
DEF-315 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITY (BENEFIT2)
January 7, 2021 updated by: Lantheus Medical Imaging
A Phase III, Open-Label, Multicenter Trial to Evaluate Ejection Fraction, End-Diastolic and End-Systolic Volumes, by Unenhanced and DEFINITY®-Enhanced 2D-Echo and Magnetic Resonance Imaging
This is a Phase 3, prospective, open-label, multicenter study to evaluate Left Ventricular Ejection Fraction (LVEF) measurement accuracy and reproducibility of DEFINITY® contrast-enhanced and unenhanced echocardiography as compared with non-contrast cardiac magnetic resonance imaging (CMR) used as the truth standard.
Study Overview
Study Type
Interventional
Enrollment (Actual)
160
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Tucson, Arizona, United States, 85724
- Banner University of Arizona Medical Center
-
-
California
-
Los Angeles, California, United States, 90048
- Cedars Sinai
-
Orange, California, United States, 92868
- University of California-Irvine
-
San Diego, California, United States, 92037
- UC San Diego
-
-
Delaware
-
Wilmington, Delaware, United States, 19803
- Alfieri Cardiology
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern Medical Group
-
-
Indiana
-
Bloomington, Indiana, United States, 46202
- Indiana University
-
-
Kentucky
-
Paducah, Kentucky, United States, 42003
- Baptist Hospital
-
-
Minnesota
-
Coon Rapids, Minnesota, United States, 55433
- Mercy Unit Hospital
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- University of Cincinnati Medical Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- University of Oklahoma
-
-
Oregon
-
Portland, Oregon, United States, 97240
- Oregon Health and Sciences University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19412
- Albert Einstein Medical Center
-
-
Texas
-
Temple, Texas, United States, 76501
- Baylor Scott White Research Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Men and women ≥ 18 years of age in sinus rhythm
- Able to communicate effectively with trial personnel
- LVEF measurements obtained via 2D Echo with or without contrast obtained within 6 months prior to enrollment (Day 0)
- Has provided signed informed consent after receiving a verbal and written explanation of this clinical trial
Exclusion Criteria:
- Female subjects who are pregnant or lactating. All women of child bearing potential [WOCBP] must have a negative urine pregnancy test at screening regardless of contraceptive use history.
Women of child-bearing potential are excluded unless they:
- are post-menopausal defined as amenorrhea ≥ 12 consecutive months, OR
- have undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy), OR
- have been using an adequate and medically approved method of contraception to avoid pregnancy for at least 1 month prior to DEFINITY® dose administration and be willing to continue using the same method for the duration of the study.
- Current illness or pathology that would prevent undergoing investigational product administration due to a significant safety risk to the patient.
- Uncontrolled arterial hypertension (defined as systolic blood pressure ≥ 200 mmHg or diastolic blood pressure ≥ 110 mmHg) or arterial hypotension (defined as systolic blood pressure ≤ 90 mmHg).
Unstable cardiovascular status defined as:
- myocardial infarction or unstable angina pectoris within 6 months prior to enrollment/DEFINITY® dose administration day
- transient ischemic attack or stroke within 3 months prior to DEFINITY® dose administration
- symptomatic valvular heart disease or moderate to severe stenotic valvular heart disease
- clinically significant congenital heart defects
- current uncontrolled cardiac arrhythmias causing symptoms or hemodynamic compromise
- acute pulmonary embolus or pulmonary infarction
- acute myocarditis or pericarditis
- acute aortic dissection
- atrial fibrillation
- any major surgery within 4 weeks prior to screening
- known contraindications to undergoing CMR (e.g. implanted pacemakers, cardioverter, defibrillators) or claustrophobia
- participation in any investigational drug, device, or placebo study within 30 days prior to screening
- known hypersensitivity to perflutren, or any of the excipients in DEFINITY®
- prisoners or those who are subject to compulsory detention or involuntary incarceration for treatment of either a psychiatric or physical illness (e.g., infectious disease).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: DEFINITY®
Each patient will undergo an unenhanced ultrasound examination and a DEFINITY® contrast-enhanced ultrasound
|
All subjects will receive a single dose of DEFINITY®
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Absolute Value of LVEF Percentage Differences From CMR by Blinded Reader
Time Frame: Up to 30 days between day of echocardiograms and CMR imaging
|
Demonstrate improvement in accuracy in left ventricular ejection fraction (LVEF) assessment using DEFINITY® contrast-enhanced over unenhanced echocardiography by comparing LVEF percentage differences from CMR measured by 3 independent blinded image readers.
|
Up to 30 days between day of echocardiograms and CMR imaging
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Secondary Objective 1: Absolute Value of LVEF Percentage Differences From CMR by Blinded Reader for Sub-optimal Echocardiograms
Time Frame: Up to 30 days between day of echocardiogram and CMR imaging
|
Demonstrate improvement in accuracy in left ventricular ejection fraction (LVEF) assessment using DEFINITY® contrast-enhanced over unenhanced echocardiography in subjects with suboptimal echocardiograms by comparing LVEF percentage differences from CMR measured by 3 independent blinded readers.
|
Up to 30 days between day of echocardiogram and CMR imaging
|
Secondary Objective 2: Absolute Value LVEF Percentage Differences From CMR Between Blinded Readers
Time Frame: Up to 30 days between day of echocardiograms and CMR imaging
|
Demonstrate a reduction in inter-reader variability for the assessment of left ventricular ejection fraction using DEFINITY® contrast-enhanced versus unenhanced echocardiography by comparing LVEF percentage differences from CMR between 3 independent blinded readers.
|
Up to 30 days between day of echocardiograms and CMR imaging
|
Secondary Objective 3: Absolute Value End-diastolic and Systolic Volume Differences From CMR Between Blinded Readers
Time Frame: Up to 30 days between day of echocardiogram and CMR imaging
|
Demonstrate a reduction in inter-reader variability for the assessment of end-diastolic/systolic volumes using DEFINITY® contrast-enhanced versus unenhanced echocardiography by comparing end-diastolic and systolic volume differences from CMR between 3 independent blinded readers.
|
Up to 30 days between day of echocardiogram and CMR imaging
|
Secondary Objective 4: Absolute Value of LVEF Percentage Differences From CMR Between Readers for Sub-optimal Echocardiograms
Time Frame: Up to 30 days between day of echocardiograms and CMR imaging
|
Demonstrate a reduction in inter-reader variability for the assessment of left ventricular ejection fraction using DEFINITY® contrast-enhanced versus unenhanced echocardiography by comparing LVEF percentage differences from CMR between 3 independent blinded readers in subjects with suboptimal echocardiograms.
|
Up to 30 days between day of echocardiograms and CMR imaging
|
Secondary Objective 5: Absolute Value End-diastolic and Systolic Volume Differences From CMR Between Blinded Readers for Suboptimal Echocardiograms
Time Frame: Up to 30 days between day of echocardiograms and CMR imaging
|
Demonstrate a reduction in inter-reader variability for the assessment of end-diastolic/systolic volumes using DEFINITY® contrast-enhanced versus unenhanced echocardiography by comparing end-diastolic and systolic volume differences from CMR between 3 independent blinded readers in subjects with suboptimal echocardiograms.
|
Up to 30 days between day of echocardiograms and CMR imaging
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
December 28, 2018
Primary Completion (ACTUAL)
January 9, 2020
Study Completion (ACTUAL)
January 9, 2020
Study Registration Dates
First Submitted
September 28, 2018
First Submitted That Met QC Criteria
October 23, 2018
First Posted (ACTUAL)
October 25, 2018
Study Record Updates
Last Update Posted (ACTUAL)
January 28, 2021
Last Update Submitted That Met QC Criteria
January 7, 2021
Last Verified
November 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- DEF-315
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiac Disease
-
University of British ColumbiaRecruitingSurgery | Cardiac Event | Cardiac Disease | Cardiac Complication | Cardiac Valve Disease | Surgery-ComplicationsCanada
-
Istituto Auxologico ItalianoRecruitingCardiovascular Diseases | Cardiomyopathies | Ischemic Heart Disease | Sudden Cardiac Death Due to Cardiac ArrhythmiaItaly
-
Ostfold University CollegeNot yet recruitingCardiac Arrest | Cardiac Arrhythmia | Cardiac Disease | Cardiac Death
-
Johns Hopkins UniversityNational Human Genome Research Institute (NHGRI)Enrolling by invitationGenetic Counseling | Inherited Cardiac DiseaseUnited States
-
Centro Medico TeknonRecruitingMyocardial Infarction | Ischemic Heart Disease | Ventricular Tachycardia | Magnetic Resonance Imaging | Ventricular Arrythmia | Sudden Cardiac Death | Sudden Cardiac Death Due to Cardiac ArrhythmiaSpain
-
Children's Healthcare of AtlantaTerminated
-
Beijing Chao Yang HospitalBeijing Boren Hospital; Beijing Chuiyangliu HospitalNot yet recruitingM-protein Related Cardiac Disease
-
Maastricht University Medical CenterActive, not recruitingHeart Diseases | Cardiac Conduction DefectNetherlands
-
US Department of Veterans AffairsCompleted
-
Vanderbilt University Medical CenterCompletedCardiac DiseasesUnited States
Clinical Trials on DEFINITY®
-
Washington University School of MedicineNational Cancer Institute (NCI)RecruitingGlioblastoma | Glioblastoma MultiformeUnited States
-
Lantheus Medical ImagingCompletedCardiovascular DiseaseUnited States
-
University of WashingtonRecruiting
-
University of LouisvilleTerminatedLiver TumorsUnited States
-
University of AlbertaCanadian VIGOUR CentreRecruitingST Elevation Myocardial InfarctionCanada
-
University of North Carolina, Chapel HillVanderbilt University; North Carolina Translational and Clinical Sciences InstituteCompletedChronic Kidney Disease | Cystic Kidney DiseaseUnited States
-
Lantheus Medical ImagingCompletedVentricular Ejection FractionUnited States
-
University of VirginiaCompletedType 1 DiabetesUnited States
-
UNC Lineberger Comprehensive Cancer CenterCompletedKidney CancerUnited States
-
Dr. Amer JohriLantheus Medical ImagingRecruitingMyocardial Infarction | Cardiovascular Diseases | Atherosclerosis | Carotid Artery Diseases | Acute Coronary Syndrome | Ischemic Heart DiseaseCanada